黄芪通络汤联合VRD化疗方案治疗初诊多发性骨髓瘤患者的效果  

Effects of Huangqi Tongluo decoction combined with VRD chemotherapy in treatment of newly diagnosed multiple myeloma patients

作　　者：赵蕾 ZHAO Lei(Department of Oncology and Hematology of Pingliang Second People’s Hospital,Pingliang 744000 Gansu,China)

机构地区：[1]平凉市第二人民医院肿瘤血液科,甘肃平凉744000

出　　处：《中国民康医学》2024年第2期87-90,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察黄芪通络汤联合VRD化疗方案治疗初诊多发性骨髓瘤患者的效果。方法:选取2021年1月至2023年1月该院收治的80例初诊多发性骨髓瘤患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各40例。对照组采用VRD化疗方案(硼替佐米+来那度胺+地塞米松)治疗,研究组在对照组基础上联合黄芪通络汤治疗,21 d为1个疗程,两组均治疗2个疗程。比较两组临床疗效,治疗前后中医证候积分、肿瘤标志物[β_(2)-微球蛋白(β_(2)-MG)、M蛋白]水平、凝血功能指标[凝血酶原时间(PT)、D-二聚体(D-D)、纤维蛋白原(FIB)]水平,以及不良反应发生率。结果:研究组客观缓解率(ORR)为90.00%(36/40),高于对照组的72.50%(29/40),差异有统计学意义(P<0.05);治疗后,研究组肢体麻木刺痛、胸闷有痰、疲倦乏力等中医证候积分均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组M蛋白、β_(2)-MG、PT、FIB、D-D水平均低于对照组,差异有统计学意义(P<0.05);两组恶心呕吐、皮疹、血小板减少等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:黄芪通络汤联合VRD化疗方案治疗初诊多发性骨髓瘤患者可提高ORR,降低中医证候积分、肿瘤标志物水平和凝血功能指标水平,效果优于单纯VRD化疗方案治疗。Objective:To observe effects of Huangqi Tongluo decoction combined with VRD chemotherapy in treatment of newly diagnosed multiple myeloma patients.Methods:A prospective study was conducted on 80 patients with newly diagnosed multiple myeloma admitted to the hospital from January 2021 to January 2023.According to the random number table method,they were divided into control group and study group,40 cases in each group.The control group was treated with VRD chemotherapy regimen(Bortezomib+Lenalidomide+Dexamethasone),while the study group was treated with Huangqi Tongluo decoction on the basis of that of the control group.21 d was a course of treatment.Both groups were treated for 2 courses.The clinical efficacy,the TCM syndrome scores,the tumor markers[β_(2)-microglobulin(β_(2)-MG),M protein]levels,the coagulation function indexes[prothrombin time(PT),D-dimer(D-D),fibrinogen(FIB)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective response rate(ORR)of the study group was 90.00%(36/40),which was higher than 72.50%(29/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of TCM syndromes such as numbness and tingling of limbs,chest tightness and phlegm,and fatigue in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of M protein,β_(2)-MG,PT,FIB and D-D in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as nausea and vomiting,rash and thrombocytopenia between the two groups(P>0.05).Conclusions:Huangqi Tongluo decoction combined with VRD chemotherapy in the treatment of the newly diagnosed multiple myeloma patients can improve the ORR and reduce the TCM syndrome scores,the tumor marker levels and the coagulation function inde

关 键 词：黄芪通络汤 硼替佐米 来那度胺 多发性骨髓瘤 凝血功能 肿瘤标志物 中医证候积分 

分 类 号：R733.3[医药卫生—肿瘤]